OneSource Specialty Pharma Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing mixed performance amid operational challenges. The pharmaceutical contract development and manufacturing organization (CDMO) reported its Q3 FY26 results following board approval on January 23, 2026.

Consolidated Financial Performance

The company's consolidated operations reflected challenging market conditions during the quarter. Revenue from operations declined to ₹2,903.40 million in Q3 FY26 compared to ₹3,925.63 million in Q3 FY25.

For the nine-month period ended December 31, 2025, consolidated revenue from operations reached ₹9,933.73 million compared to ₹10,189.00 million in the corresponding period of FY25, indicating a decline of 2.51%.

Standalone Results Analysis

On a standalone basis, the company reported revenue from operations of ₹2,902.20 million for Q3 FY26, down from ₹3,367.49 million in Q3 FY25. The standalone net loss widened to ₹621.85 million compared to ₹730.23 million loss in the previous year's quarter.

Exceptional Items and Operational Costs

The company recorded exceptional items totaling ₹70.90 million during Q3 FY26, comprising employee one-time mutual separation settlement of ₹41.47 million and gratuity and compensated absences impact under new labor codes of ₹29.43 million. This compares to exceptional items of ₹1,005.23 million in Q3 FY25, which primarily included business combination and listing-related expenses.

Total consolidated expenses for the quarter amounted to ₹3,808.86 million, with significant components including:

• Employee benefits expenses: ₹641.92 million
• Depreciation and amortization: ₹696.37 million
• Finance costs: ₹382.31 million
• Other expenses: ₹1,144.60 million

Corporate Developments

The company has entered into a Composite Scheme of Arrangement and Amalgamation involving multiple entities including Brooks Steriscience Limited, Steriscience Pte Limited, and Strides Pharma Services Private Limited. The scheme, approved by the Board of Directors on September 26, 2025, is currently awaiting regulatory approvals.

Additionally, on December 22, 2025, the company approved an amalgamation of its wholly-owned subsidiaries Stelis Pte. Ltd. and OneSource Specialty Pte. Ltd. under Singapore's Companies Act. The amalgamation received regulatory approval on January 14, 2026, and became effective from January 1, 2026.

Segment Performance

The company operates primarily in the CDMO segment, which reported revenue of ₹2,903.40 million for Q3 FY26 compared to ₹3,925.63 million in Q3 FY25. The segment recorded a loss before tax of ₹930.11 million during the quarter, compared to a loss of ₹665.02 million in the corresponding previous quarter.

OneSource Specialty Pharma Limited has successfully allotted 36,065 equity shares under its Employee Stock Option Plan 2021 to eligible employees. The Management Committee approved this allotment during its meeting held on January 21, 2026, marking another milestone in the company's employee incentive program.

Share Allotment Details

The allotment was executed under the OneSource Specialty Pharma Limited – Employee Stock Option Plan 2021 (ONESOURCE ESOP 2021), with employees exercising their vested options. The key parameters of this allotment are presented below:

Impact on Share Capital Structure

The allotment has resulted in an expansion of the company's equity base. The paid-up share capital witnessed an increase following the incorporation of these new shares:

Regulatory Compliance and Share Characteristics

The allotment was conducted in full compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company had previously filed the required statement under Regulation 10(b) with stock exchanges on March 12, 2025.

The newly allotted equity shares carry the following characteristics:

• Rank pari passu with existing equity shares in all respects
• No lock-in restrictions applicable
• Identical to existing shares in terms of rights and privileges
• Listed on BSE Limited and National Stock Exchange of India Limited

Corporate Governance Framework

The allotment process was overseen by the Management Committee and executed under the supervision of Company Secretary and Compliance Officer Trisha A (Membership Number: A47635). The company maintains its registered office at Unit No. 902, "Cyber One", Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai 400703, ensuring proper governance standards throughout the process.

This ESOP allotment reflects OneSource Specialty Pharma's commitment to employee participation in the company's growth story while maintaining strict adherence to regulatory requirements and corporate governance practices.